Skip to content
DataLookout
Menu

NCT06062745

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Sep 1, 2026 to Sep 1, 2027
    • Eligibility criteria expanded, about 13 words
    • Interventions: 18F-fluciclovine (Drug), PET/CT (Device) to 18F-fluciclovine (Drug), PET/CT (Device)
    • Site contacts updated at 1 of 2 sites
  2. Minor Site contacts updated at 1 of 2 sitesv4
  3. Minor Site contacts updated at 1 of 2 sitesv3
  4. Notable Lead sponsor: Dana-Farber Cancer Institute to Brigham and Women's Hospital
    • Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2024 to Feb 1, 2024
    • Site details revised at 2 of 2 sites
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Fluciclovine and PSMA Uptake in PSMA Positive Tumors
Timeframe: Up to 6 months
Fluciclovine and PSMA Uptake in PSMA Negative Tumors
Timeframe: up to 6 months

Arms and interventions

18F-fluciclovineExperimental

Participants with low prostate-specific membrane antigen (PSMA) expression or neuroendocrine prostate cancer will receive: * 18F-fluciclovine PET/CT within 6 weeks of standard of care exam and 68Ga-PSMA PET/CT * 2x Blood test at time of 18F-fluciclovine PET/CT and prior to treatment as determined by participants primary oncologist

Drugs: 18F-fluciclovine

Devices: PET/CT

Sites

2 sites in 1 country